Asia Pacific Pharmaceutical (002370.SZ) released its 2023 annual report. The company achieved operating income of 4 during the reporting period...
According to Zhitong Finance App, Asia Pacific Pharmaceutical (002370.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 421 million yuan, an increase of 12.64%; net loss attributable to shareholders of listed companies was 11.877 million yuan, narrowing the year-on-year loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 689.445 million yuan per share; basic loss per share.
Due to reasons such as selecting the 7th batch of centralized national pharmaceutical procurement from the company's 3 products, the main business revenue increased compared to the previous year. According to the verdicts of the Wuhan Agricultural Commercial Bank case and investor litigation case, the estimated liabilities accumulated in the previous period were recovered, and asset impairment losses decreased compared to the previous year. As a result, net profit attributable to shareholders of listed companies in 2023 decreased compared to losses in the same period last year.
